Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Next-generation Sequencing03:00

Next-generation Sequencing

The first human genome sequencing project cost $2.7 billion and was declared complete in 2003, after 15 years of international cooperation and collaboration between several research teams and funding agencies. Today, with the advent of next-generation sequencing technologies, the cost and time of sequencing a human genome have dropped over 100 fold.
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Years of life lost in patients with a false-negative diagnosis of primary melanoma. A prospective study of the German Central Malignant Melanoma Registry involving 9063 patients over 28 years.

Nature communications·2026
Same author

Nail Clubbing-Associated With a Large Segmental Infantile Hemangioma of the Arm in a Patient With PHACES Syndrome.

Pediatric dermatology·2026
Same author

In-depth Human Phenotype Ontology Curation Boosts Prioritization Performance for Netherton Syndrome.

The British journal of dermatology·2026
Same author

Depicting the Immunological Landscape of Basal Cell Carcinoma Subtypes.

Journal of cutaneous pathology·2026
Same author

NLRP1 inflammasome activation in skin equivalents reveals mechanistic insights into the roles of keratinocytes in psoriasis.

Cell death & disease·2026
Same author

NGFR induces melanoma invasion and immunotherapy resistance through myosin light chain 2 modulation.

The EMBO journal·2026
Same journal

RETRACTED: Sabir et al. DNA Based and Stimuli-Responsive Smart Nanocarrier for Diagnosis and Treatment of Cancer: Applications and Challenges. <i>Cancers</i> 2021, <i>13</i>, 3396.

Cancers·2026
Same journal

Correction: Adeluola et al. Chemoprevention of 4-NQO-Induced Oral Cancer by the Combination of Resveratrol and EGCG: In Vivo, In Silico and In Vitro Studies. <i>Cancers</i> 2026, <i>18</i>, 1098.

Cancers·2026
Same journal

Correction: Peñalver et al. Guidelines for Diagnosis, Treatment, and Follow-Up of Patients with Follicular Lymphoma-Spanish Lymphoma Group (GELTAMO) 2026. <i>Cancers</i> 2026, <i>18</i>, 395.

Cancers·2026
Same journal

Correction: Accorsi Buttini et al. Development of a Simplified Geriatric Score-4 (SGS-4) to Predict Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation in Patients Aged over 50. <i>Cancers</i> 2025, <i>17</i>, 3278.

Cancers·2026
Same journal

Age-Stratified Long-Term Outcomes of Immune Checkpoint Inhibitors for Stage IV Melanoma and NSCLC in The Netherlands: A Population-Based Study.

Cancers·2026
Same journal

Targeting Ferroptosis in Glioblastoma: Molecular Mechanisms, Tumor Microenvironment, and Therapeutic Opportunities.

Cancers·2026
See all related articles

Related Experiment Video

Updated: Jun 5, 2026

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

11.7K

A Retrospective Analysis of Ambiguous Spitz Tumors Using Next-Generation Sequencing.

Mario Teufer1,2, Martin Theiler2,3, Joana Lanz2,3,4

  • 1Department of Dermatology, University Hospital Zurich, 8091 Zurich, Switzerland.

Cancers
|April 14, 2025
PubMed
Summary
This summary is machine-generated.

Next-generation sequencing (NGS) and immunohistochemistry (IHC) improve Spitz tumor (ST) diagnosis. Combining these methods helps differentiate benign Spitz nevi from atypical Spitz tumors and Spitz melanoma, guiding risk assessment and patient management.

Keywords:
Spitz tumorsatypical Spitz tumorsimmunohistochemistrymelanoma-specific panelnext-generation sequencing

More Related Videos

Comparative Lesions Analysis Through a Targeted Sequencing Approach
08:16

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

6.7K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

990

Related Experiment Videos

Last Updated: Jun 5, 2026

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

11.7K
Comparative Lesions Analysis Through a Targeted Sequencing Approach
08:16

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

6.7K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

990

Area of Science:

  • Dermatopathology
  • Oncology
  • Molecular Diagnostics

Background:

  • Spitz tumors (STs) present diagnostic challenges due to overlapping features and variable malignant potential.
  • Histological and immunohistochemical (IHC) analyses alone are often insufficient for accurate ST classification.
  • Distinguishing benign from malignant melanocytic lesions is crucial for appropriate clinical management.

Purpose of the Study:

  • To evaluate the diagnostic utility of a melanoma-specific next-generation sequencing (NGS) panel (MelArray) combined with IHC.
  • To improve the assessment of diagnostically challenging Spitz tumor cases.
  • To correlate molecular and IHC findings with patient outcomes.

Main Methods:

  • Retrospective analysis of patients with Spitz tumors and available MelArray NGS results.
  • Evaluation of molecular alterations (genetic mutations, TMB, CNV), IHC scores (p16, Ki-67, HMB45, PRAME, Melan A), and clinical data.
  • Correlation of integrated diagnostic data with patient follow-up and outcomes.

Main Results:

  • Atypical Spitz tumors (ASTs) showed heterozygous deletions but lacked multiple damaging mutations typical of melanoma.
  • Spitz nevi (SN) exhibited minimal genetic alterations and low IHC scores, consistent with a benign profile.
  • Spitz melanoma (SM) displayed a distinct molecular profile with damaging mutations, high TMB, and IHC scores similar to ASTs.

Conclusions:

  • Integrating NGS (MelArray panel) with histology and IHC enhances diagnostic accuracy for challenging STs.
  • This combined approach identifies genetic alterations associated with malignancy risk, aiding in risk stratification.
  • The findings support improved detection of high-risk lesions requiring closer follow-up and better prediction of benign courses.